Arch Therapeutics announced an expansion of its contracted sales force with a dedicated team of independent representatives whose primary objective will be to support surgeons and other medical professionals as well as advance the commercialization of AC5 Advanced Wound System in high volume government facilities. The Company is on schedule to add approximately fifteen independent commission-based sales representatives by the end of Q1 2023 dedicated to supporting AC5, Arch’s self-assembling wound care product, in federal government agencies, including the Department of Veterans Affairs, Indian Health Services, Department of Defense and Medical Treatment Facilities. These additional representatives will be deployed to optimize opportunities in newly created sales regions and in current regions that have had initial and restocking orders for AC5.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARTH:
- Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
- Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
- Arch Therapeutics forms Medical Advisory Board
- Arch Therapeutics announces 1-for-200 reverse stock split
- Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
